• Explore /
  • Poster
  • / Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.

Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.

Abstract Poster

Authors

null

Francisco Robert

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL

Francisco Robert , Ecaterina Elena Dumbrava , Yan Xing , Elizabeth Mills , James L. Freddo , Charles P. Theuer , Bonne J. Adams , James Lawrence , Alicia A Trigeiro , Claire Xu , Yuan Meng , Linda Lee , Yonggang Zhao , Jerry Wang , Huaqiong Joan Shen , Michael S. Gordon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Clinical Trial Registration Number

NCT03835949

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2511)

DOI

10.1200/JCO.2021.39.15_suppl.2511

Abstract #

2511

Abstract Disclosures

Similar Posters

First Author: Kristoffer Staal Rohrberg

First Author: Ye Guo

First Author: Jermaine Coward

First Author: James J. Harding